Cargando…

Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension

Pulmonary arterial hypertension is a complex disease resulting from the interplay of myriad biological and environmental processes that lead to remodeling of the pulmonary vasculature with consequent pulmonary hypertension. Despite currently available therapies, there remains significant morbidity a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemnes, Anna, Rothman, Alexander M.K., Swift, Andrew J., Zisman, Lawrence S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682212/
https://www.ncbi.nlm.nih.gov/pubmed/33282185
http://dx.doi.org/10.1177/2045894020957234
_version_ 1783612666652131328
author Hemnes, Anna
Rothman, Alexander M.K.
Swift, Andrew J.
Zisman, Lawrence S.
author_facet Hemnes, Anna
Rothman, Alexander M.K.
Swift, Andrew J.
Zisman, Lawrence S.
author_sort Hemnes, Anna
collection PubMed
description Pulmonary arterial hypertension is a complex disease resulting from the interplay of myriad biological and environmental processes that lead to remodeling of the pulmonary vasculature with consequent pulmonary hypertension. Despite currently available therapies, there remains significant morbidity and mortality in this disease. There is great interest in identifying and applying biomarkers to help diagnose patients with pulmonary arterial hypertension, inform prognosis, guide therapy, and serve as surrogate endpoints. An extensive literature on potential biomarker candidates is available, but barriers to the implementation of biomarkers for clinical use in pulmonary arterial hypertension are substantial. Various omic strategies have been undertaken to identify key pathways regulated in pulmonary arterial hypertension that could serve as biomarkers including genomic, transcriptomic, proteomic, and metabolomic approaches. Other biologically relevant components such as circulating cells, microRNAs, exosomes, and cell-free DNA have recently been gaining attention. Because of the size of the datasets generated by these omic approaches and their complexity, artificial intelligence methods are being increasingly applied to decipher their meaning. There is growing interest in imaging the lung with various modalities to understand and visualize processes in the lung that lead to pulmonary vascular remodeling including high resolution computed tomography, Xenon magnetic resonance imaging, and positron emission tomography. Such imaging modalities have the potential to demonstrate disease modification resulting from therapeutic interventions. Because right ventricular function is a major determinant of prognosis, imaging of the right ventricle with echocardiography or cardiac magnetic resonance imaging plays an important role in the evaluation of patients and may also be useful in clinical studies of pulmonary arterial hypertension.
format Online
Article
Text
id pubmed-7682212
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76822122020-12-03 Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension Hemnes, Anna Rothman, Alexander M.K. Swift, Andrew J. Zisman, Lawrence S. Pulm Circ Research Article Pulmonary arterial hypertension is a complex disease resulting from the interplay of myriad biological and environmental processes that lead to remodeling of the pulmonary vasculature with consequent pulmonary hypertension. Despite currently available therapies, there remains significant morbidity and mortality in this disease. There is great interest in identifying and applying biomarkers to help diagnose patients with pulmonary arterial hypertension, inform prognosis, guide therapy, and serve as surrogate endpoints. An extensive literature on potential biomarker candidates is available, but barriers to the implementation of biomarkers for clinical use in pulmonary arterial hypertension are substantial. Various omic strategies have been undertaken to identify key pathways regulated in pulmonary arterial hypertension that could serve as biomarkers including genomic, transcriptomic, proteomic, and metabolomic approaches. Other biologically relevant components such as circulating cells, microRNAs, exosomes, and cell-free DNA have recently been gaining attention. Because of the size of the datasets generated by these omic approaches and their complexity, artificial intelligence methods are being increasingly applied to decipher their meaning. There is growing interest in imaging the lung with various modalities to understand and visualize processes in the lung that lead to pulmonary vascular remodeling including high resolution computed tomography, Xenon magnetic resonance imaging, and positron emission tomography. Such imaging modalities have the potential to demonstrate disease modification resulting from therapeutic interventions. Because right ventricular function is a major determinant of prognosis, imaging of the right ventricle with echocardiography or cardiac magnetic resonance imaging plays an important role in the evaluation of patients and may also be useful in clinical studies of pulmonary arterial hypertension. SAGE Publications 2020-11-18 /pmc/articles/PMC7682212/ /pubmed/33282185 http://dx.doi.org/10.1177/2045894020957234 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Article
Hemnes, Anna
Rothman, Alexander M.K.
Swift, Andrew J.
Zisman, Lawrence S.
Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension
title Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension
title_full Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension
title_fullStr Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension
title_full_unstemmed Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension
title_short Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension
title_sort role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682212/
https://www.ncbi.nlm.nih.gov/pubmed/33282185
http://dx.doi.org/10.1177/2045894020957234
work_keys_str_mv AT hemnesanna roleofbiomarkersinevaluationtreatmentandclinicalstudiesofpulmonaryarterialhypertension
AT rothmanalexandermk roleofbiomarkersinevaluationtreatmentandclinicalstudiesofpulmonaryarterialhypertension
AT swiftandrewj roleofbiomarkersinevaluationtreatmentandclinicalstudiesofpulmonaryarterialhypertension
AT zismanlawrences roleofbiomarkersinevaluationtreatmentandclinicalstudiesofpulmonaryarterialhypertension